Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Operating Expenses: 2018-2024

Historic Other Operating Expenses for Agios Pharmaceuticals (AGIO) over the last 5 years, with Dec 2024 value amounting to $200.0 million.

  • Agios Pharmaceuticals' Other Operating Expenses fell 99.16% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year decrease of 97.18%. This contributed to the annual value of $200.0 million for FY2024, which is 6842.03% up from last year.
  • According to the latest figures from FY2024, Agios Pharmaceuticals' Other Operating Expenses is $200.0 million, which was up 6,842.03% from $2.9 million recorded in FY2023.
  • In the past 5 years, Agios Pharmaceuticals' Other Operating Expenses registered a high of $200.0 million during FY2024, and its lowest value of $1.7 million during FY2022.
  • Over the past 3 years, Agios Pharmaceuticals' median Other Operating Expenses value was $2.9 million (recorded in 2023), while the average stood at $68.2 million.
  • In the last 5 years, Agios Pharmaceuticals' Other Operating Expenses slumped by 74.33% in 2022 and then skyrocketed by 6,842.03% in 2024.
  • Agios Pharmaceuticals' Other Operating Expenses (Yearly) stood at $6.6 million in 2021, then slumped by 74.33% to $1.7 million in 2022, then skyrocketed by 69.07% to $2.9 million in 2023, then soared by 6,842.03% to $200.0 million in 2024.